Stargardt Disease Drugs and Pipeline Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NDA Approval, Mechanism of Action, Route of Administration, Therapeutic Assessment and Companies by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Stargardt Disease Pipeline Report:
• Stargardt Disease Companies across the globe are diligently working toward developing novel Stargardt Disease treatment therapies with a considerable amount of success over the years.
• Stargardt Disease companies working in the treatment market are Ocugen, Belite Bio, Inc, Alkeus Pharmaceuticals, Biophytis, reVision Therapeutics, Inc, IVERIC bio, Inc., Nanoscope Therapeutics, Belite Bio, Kubota Vision, and others, are developing therapies for the Stargardt Disease treatment
• Emerging Stargardt Disease therapies in the different phases of clinical trials are- OCU410ST, Tinlarebant, ALK-001, BIO-201, REV-0100, Avacincaptad pegol, MCO-010, LBS-008, Emixustat, and others are expected to have a significant impact on the Stargardt Disease market in the coming years.
• In March 2025, Barcelona-based genetic medicines company, SpliceBio, has administered the first dose in the Phase 1/2 ASTRA clinical trial (NCT identifier pending) evaluating SB-007, a dual adeno-associated virus (AAV) vector-based gene therapy for Stargardt disease. This inherited retinal disorder, caused by mutations in the ABCA4 gene, leads to progressive vision loss and currently has no approved treatments. Affecting approximately 1 in 8,000 to 10,000 people, it is the most common form of inherited juvenile macular degeneration.
• In February 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has secured alignment with the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2/3 pivotal confirmatory trial for OCU410ST. If the trial yields positive results, it could serve as the foundation for a biologics license application (BLA) submission.
• In January 2025, Alkeus Pharmaceuticals, Inc., a biopharmaceutical company focused on retinal disease treatment, has reported positive interim results from its TEASE-3 study. The data indicate that early-stage Stargardt disease patients receiving oral gildeuretinol acetate exhibited no disease progression and maintained stable visual acuity over multiple years.
• In September 2024, Nanoscope Therapeutics Inc., a clinical-stage biotechnology firm focused on gene therapies for retinal degenerative diseases and age-related macular degeneration (AMD), announced a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The meeting focused on the clinical program assessing MCO-010 for treating severe vision loss caused by Stargardt Macular Degeneration (SMD), paving the way for the progression of MCO-010 to a Phase 3 registrational trial.
• In May 2024, Alkeus Pharmaceuticals, Inc. has revealed that additional favorable findings from its TEASE-3 clinical trial investigating gildeuretinol in adolescent and young-adult patients with early-stage Stargardt disease will be disclosed at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.
• In April 2024, The Data Safety and Monitoring Board (DSMB) has approved advancement to the medium dose in Ocugen's OCU410ST clinical trial for Stargardt disease. This decision comes after confirming the safety and tolerability of the low dose of modifier gene therapy OCU410ST, representing a notable progression in the trial's dose-escalation phase. Ocugen has disclosed that three patients have received the low dose in the Phase I/II clinical trial for Stargardt disease.
• In March 2024, Belite Bio has applied to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a clinical trial of Tinlarebant for treating adolescent Stargardt disease (STGD1). Named DRAGON II, this trial includes a Phase Ib open-label study and a Phase II/III global study. The Phase Ib study is tailored to evaluate the pharmacokinetics and pharmacodynamics of tinlarebant in Japanese adolescent STGD1 patients.
• In February 2024, Ocugen has declared the conclusion of subject dosing in the initial cohort of its Phase I/II GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate intended for the treatment of Stargardt disease. This achievement represents a notable advancement in addressing the genetic eye condition associated with retinal degeneration and vision impairment. OCU410ST utilizes an adeno-associated virus (AAV) delivery system to administer the RAR Related Orphan Receptor A (RORA) gene to the retina.
• In January 2024, Ascidian Therapeutics, a biotechnology company focused on treating human diseases through RNA manipulation, has announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application and awarded Fast Track designation for ACDN-01. ACDN-01 is the first-ever clinical-stage RNA exon editor and the sole clinical-stage therapy designed to target the genetic root of Stargardt disease. Ascidian anticipates commencing enrollment in the Phase 1/2 STELLAR study of ACDN-01 for Stargardt disease and other ABCA4 retinopathies in the first half of 2024.

Stargardt Disease Overview
Stargardt Disease is a rare inherited retinal disorder that primarily affects children and young adults, leading to progressive vision loss. Stargardt Disease results from mutations in the ABCA4 gene, which causes the build-up of toxic vitamin A byproducts in the retina, damaging the macula - the central part of the retina responsible for sharp, straight-ahead vision. Stargardt Disease symptoms typically begin with difficulty in reading, blurry vision, and trouble seeing in low light conditions. Stargardt Disease progression varies from person to person, but most individuals eventually experience significant central vision loss while retaining peripheral vision.

Stargardt Disease diagnosis involves a combination of tests such as fundus autofluorescence, optical coherence tomography (OCT), and genetic testing to confirm ABCA4 mutations. Stargardt Disease currently has no approved cure, but supportive therapies like visual aids and low-vision rehabilitation can help patients maintain independence. Stargardt Disease research is advancing, with clinical trials exploring gene therapies, stem cell-based treatments, and pharmacological approaches to slow or halt retinal degeneration. Stargardt Disease awareness is essential for early detection and access to emerging treatments. Stargardt Disease management requires a multidisciplinary approach, involving ophthalmologists, genetic counselors, and low-vision specialists to optimize patient care and quality of life.

Get a Free Sample PDF Report to know more about Stargardt Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Stargardt Disease Drugs Under Different Phases of Clinical Development Include:
• OCU410ST: Ocugen
• Tinlarebant: Belite Bio, Inc
• ALK-001: Alkeus Pharmaceuticals
• BIO-201: Biophytis
• REV-0100: reVision Therapeutics, Inc
• Avacincaptad pegol: IVERIC bio, Inc.
• MCO-010: Nanoscope Therapeutics
• LBS-008: Belite Bio
• Emixustat : Kubota Vision

Stargardt Disease Route of Administration
Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Stargardt Disease Molecule Type
Stargardt Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Stargardt Disease Pipeline Therapeutics Assessment
• Stargardt Disease Assessment by Product Type
• Stargardt Disease By Stage and Product Type
• Stargardt Disease Assessment by Route of Administration
• Stargardt Disease By Stage and Route of Administration
• Stargardt Disease Assessment by Molecule Type
• Stargardt Disease by Stage and Molecule Type

DelveInsight's Stargardt Disease Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Stargardt Disease product details are provided in the report. Download the Stargardt Disease pipeline report to learn more about the emerging Stargardt Disease therapies
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Stargardt Disease Therapeutics Market include:
Key companies developing therapies for Stargardt Disease are Ocugen, Belite Bio, Inc, Alkeus Pharmaceuticals, Biophytis, reVision Therapeutics, Inc, IVERIC bio, Inc., Nanoscope Therapeutics, Belite Bio, Kubota Vision, and others

Stargardt Disease Pipeline Analysis:
The Stargardt Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease Treatment.
• Stargardt Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stargardt Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stargardt Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Stargardt Disease drugs and therapies
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Stargardt Disease Pipeline Market Drivers
• Increased Research and Development Activities, new and developed robust Pipeline are some of the important factors that are fueling the Stargardt Disease Market.

Stargardt Disease Pipeline Market Barriers
• However, complications with available treatment options, lack of Disease Awareness, poor mechanism understanding for accurately predicting disease progression and other factors are creating obstacles in the Stargardt Disease Market growth.

Scope of Stargardt Disease Pipeline Drug Insight
• Coverage: Global
• Key Stargardt Disease Companies: Ocugen (NASDAQ: OCGN), Belite Bio, Inc. (NASDAQ: BLTE), Alkeus Pharmaceuticals (Private), Biophytis (EPA: ALBPS), reVision Therapeutics, Inc. (Private), IVERIC bio, Inc. (NASDAQ: ISEE), Nanoscope Therapeutics (NASDAQ: NANX), Kubota Vision (TYO: 4596), and others
• Key Stargardt Disease Therapies: OCU410ST, Tinlarebant, ALK-001, BIO-201, REV-0100, Avacincaptad pegol, MCO-010, LBS-008, Emixustat, and others
• Stargardt Disease Therapeutic Assessment: Stargardt Disease current marketed and Stargardt Disease emerging therapies
• Stargardt Disease Market Dynamics: Stargardt Disease market drivers and Stargardt Disease market barriers

Request for Sample PDF Report for Stargardt Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Stargardt Disease Report Introduction
2. Stargardt Disease Executive Summary
3. Stargardt Disease Overview
4. Stargardt Disease- Analytical Perspective In-depth Commercial Assessment
5. Stargardt Disease Pipeline Therapeutics
6. Stargardt Disease Late Stage Products (Phase II/III)
7. Stargardt Disease Mid Stage Products (Phase II)
8. Stargardt Disease Early Stage Products (Phase I)
9. Stargardt Disease Preclinical Stage Products
10. Stargardt Disease Therapeutics Assessment
11. Stargardt Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Stargardt Disease Key Companies
14. Stargardt Disease Key Products
15. Stargardt Disease Unmet Needs
16 . Stargardt Disease Market Drivers and Barriers
17. Stargardt Disease Future Perspectives and Conclusion
18. Stargardt Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.